Day: June 3, 2024

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. The fireside chat will be held on Monday, June 10, 2024, at 4:00 p.m. Eastern Time. A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com. A replay will be available on the Entrada website for 90 days following the event. About Entrada TherapeuticsEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming...

– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company – SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapeutics, today announced the closing of the sale of its manufacturing facility located in Bryan, Texas (the “Property”) to the Board of Regents of the Texas A&M University System for $8.5 million. Following the issuance of pre-funded warrants having a value of $4.5 million to the lender, Woodforest National Bank, iBio and its wholly owned subsidiary, iBio CDMO LLC, has met all of the conditions of the settlement agreement releasing the Company and its subsidiary of all obligations with respect to the debt secured by the Property....

Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, presented interim results from the Company’s Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML) in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, on June 1, 2024 in Chicago, IL. Maro Ohanian, D.O., Department of Leukemia, University of Texas MD Anderson Cancer Center, presented data showing prexigebersen...

Announces Board Leadership Changes Intends to Add Two New Trustees HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today announced that the Board of Trustees (“Board”) has appointed Amy S. Feng, an independent Trustee, as the Chair of Whitestone’s Board of Trustees, and Julia B. Buthman, also an independent Trustee, as Chair of the Board’s Nominating and Governance Committee. Mss. Feng and Buthman joined the Board in July of 2022 and May of 2023 respectively, and both have played a vital role in overseeing management’s successful turnaround strategy which has resulted in sector-leading total shareholder return of 43.7% (1) since the beginning of 2022. The Company is in the process of engaging a well-known national search firm to conduct a comprehensive search to identify two...

In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA method for detecting total body PK suggests CNTY-101 persists outside the bloodstream Enrollment continues in dose escalation phase of ELiPSE-1 at dose levels 3B (three weekly infusions of 1 billion cells) and 4A (single infusion of 3 billion cells) per cycle PHILADELPHIA, June 03, 2024 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced a poster presentation highlighting...

JUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) — Canoo Inc. (Nasdaq: GOEV), a high-tech advanced mobility company, today announced that company leadership will participate in the following investor conferences in June: Stifel Cross Sector Insight Conference Boston, MassachusettsJune 4 -5, 2024 CFO Greg Ethridge will participate in a fireside chat on June 4 at 4:10 p.m. ET. Sidoti Small Cap ConferenceVirtualJune 12-13, 2024 CFO Greg Ethridge and Vice President of Capital Markets and Investor Relations Jonathan Wolff will host a 30-minute presentation and subsequent Q&A on June 12 at 3:15 p.m. In addition to the live presentations, management will host one-on-one investor meetings at Sidoti. The above presentations will be webcast. Links to live and archived webcasts will be available from the investor relations section of the...

Colliers expands engineering capabilities into Canada TORONTO and LAVAL, June 03, 2024 (GLOBE NEWSWIRE) — Global diversified professional services and investment management company, Colliers (NASDAQ, TSX: CIGI), announced today it has entered into a definitive agreement to acquire Englobe Corporation (“Englobe”), a leading Canadian multi-discipline engineering, environmental and inspection services firm. Englobe’s senior leadership team and employee shareholders will remain shareholders in the business under Colliers’ unique partnership model. Headquartered in Laval, Québec, Englobe’s 2,800 professionals provide civil, buildings, geotechnical, and environmental engineering, material testing and related consulting services to public and private sector clients primarily in the transportation, water, buildings, and power end markets....

Program Will Continue to Trace NAL Mine Pegmatites Eastward TORONTO, June 03, 2024 (GLOBE NEWSWIRE) — Consolidated Lithium Metals Inc. (TSXV: CLM | OTCQB: JORFF | FRA: Z36) (“CLM” or the “Company“) is pleased to announce that the Phase I 2024 drilling program has commenced on the Company’s East Vallée Lithium Project, located in the Abitibi Greenstone Belt approximately 30 km northwest of Val-d’Or, Quebec (see Figure 1). The East Vallée Project is located immediate east and adjacent to the Company’s Vallée JV Project (75% CLM and 25% Sayona Mining) and only 1,000 m east and along strike of Sayona’s North American Lithium (“NAL”) Mine, the largest operating lithium mining facility in North America. On February 14, 2024, the Company announced that the Vallée JV partners had successfully traced the NAL Mine Pegmatite swarm from the...

VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: HM40) is pleased to announce that, further to its news release dated February 13, 2024, the Company has closed the purchase and sale agreement dated February 12, 2024 (the “Agreement”), under which the Company has sold Glorious Creation Limited (“Glorious”) 100% interest in its three Eastern Basin Projects, comprising seven (7) mineral claims totalling approximately 10,874 hectares (26,870 acres) located in the Province of Saskatchewan (the “Property”). ” All three projects are located in the heart of the world-renowned Eastern Athabasca Basin and hold potential for a high-grade discovery. The closing of this sale will bring exploration programs to these...

Skye provides webcast link for corporate presentation SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that Chief Executive Officer & Chair, Punit Dhillon, will present an overview of the company and its programs in obesity and glaucoma at the Jefferies Global Healthcare Conference being held in New York City from June 5th to 6th. Presentation: Wednesday, June 5, 5:00 p.m ETWebcast Link: https://wsw.com/webcast/jeff302/skye/1862592 To register for this event, please contact your sales representative. About Skye BioscienceSkye is focused on unlocking the pharmaceutical potential of the endocannabinoid...